Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

The role of pharmacogenetics as possible risk factor for rivaroxaban - associated bleeding (CROSBI ID 733139)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | domaća recenzija

Šimičević, Livija ; Slišković, Ana Marija ; Vrkić Kirhmajer, Majda ; Ganoci, Lana ; Holik, Hrvoje ; Samardžić, Jure ; Božina, Tamara The role of pharmacogenetics as possible risk factor for rivaroxaban - associated bleeding // Pharmaca. 2022. str. 141-141

Podaci o odgovornosti

Šimičević, Livija ; Slišković, Ana Marija ; Vrkić Kirhmajer, Majda ; Ganoci, Lana ; Holik, Hrvoje ; Samardžić, Jure ; Božina, Tamara

engleski

The role of pharmacogenetics as possible risk factor for rivaroxaban - associated bleeding

Introduction: Rivaroxaban has large interindividual trough concentration variability affecting its efficacy and safety, especially bleeding events. This variability could be associated with age, liver and kidney function, concomitant illness and therapy, and pharmacogenetic predisposition. Rivaroxaban is a substrate of ABCB1 and ABCG2 transporters, and CYP2J2, CYP3A4/5 enzymes. The polymorphisms of these genes may affect the pharmacokinetics of rivaroxaban and its safety profile. Aim of the study is to evaluate role of pharmacogenetics as possible risk factor for rivaroxaban-associated bleeding in patients treated for cardiovascular diseases. Patients and Methods: Presented data are part of the larger prospective nested case-control study “Pharmacogenomics in Prediction of Cardiovascular Drugs Adverse Reaction”. Clinical and laboratory data were collected. Pharmacogenetic analyses were performed using specific TaqMan® DME and SNP Assays on 7500 Real- Time PCR System for genotyping of CYP3A4*1B*22, CYP3A5*3, CYP2J2*7, c.1331- 2201T>C, ABCB1 (c.1236C>T, c.2482-2236G>A, c.2677G>T/A, c.3435C>T) and ABCG2 (c.421C>A) variants. For drug-drug interactions (DDI), The Lexicomp® Clinical Decision Support System was applied. Results: Sixteen patients (median age 73 years, range 61-80) with rivaroxaban-associated bleeding: gastrointestinal (N=9), epistaxis (N=5), haematuria (N=1) and gynaecological (N=1) were analysed. In 9/16 DDI with increased bleeding risk were found. Two patients had eGFR>90, while six patients had eGFR<60. Only three patients who experienced bleeding did not have any of investigated risk factors including gene variants. Conclusions: Our data suggest a possible role of pharmacogenetic and clinical factors and their interactions in predicting bleeding on rivaroxaban treatment. These findings indicate the need for further comprehensive research.

adverse events ; pharmacogenetics ; rivaroxaban ; risk factors

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

141-141.

2022.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Pharmaca

0031-6857

Podaci o skupu

10. hrvatski kongres farmakologije ; 1. hrvatski kongres kliničke farmakologije s međunarodnim sudjelovanjem = 10th Croatian Congress of Pharmacology ; 1st Croatian Congress of Clinical Pharmacology and Therapeutics with International Participation

poster

22.09.2022-25.09.2022

Opatija, Hrvatska

Povezanost rada

Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje), Farmacija, Interdisciplinarne prirodne znanosti, Kliničke medicinske znanosti